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Introduction: This phase III trial was conducted in non-small cell
lung cancer patients with locally advanced stage II B (only T3N0)
III A and III B (only T4 N0). Primary endpoint was 2-year survival;
secondary were toxicity, disease-free survival, and overall survival.
Methods: After three cycles of vinorelbine (N) 25 mg/m2 on days 1
and 5, ifosfamide/mesna (I) 3 g/m2 on day 1, cisplatin (P) (NIP),
patients were treated by surgery and within 45 days were random-
ized to two additional cycles of NIP versus observation.
Results: Median tumor diameter was 5.5 cm (1.2–10.6). Overall,
155 of 156 patients received chemotherapy: 133 (85%) men, median
age: 59 years (35–75). Sixty-five percentage of patients were stage
III A, 28% II B, and 7% III B. The study has been closed
prematurely because of the low inclusion rate. After three cycles of
induction in 143 assessable patients, 82 reported an objective re-
sponse (57.3%) (95% CI: 48.8–65.6), with 3.5% complete response
and 53.8% partial response. Relative dose intensity during neoadju-
vant NIP (%) was 97, 98, and 98.5 for vinorelbine, ifosfamide/
mesna, and cisplatin, respectively. Tolerance: G3 to 4 neutropenia in
3% of patients and G3 to 4 anemia in 4%; nonhematological
toxicities included G3 nausea/vomiting in 11%, G3 anorexia and G3
to 4 infection in 6.5%, G3 asthenia in 10% and G3 to 4 alopecia in
25.5%. After a median of 32 days after NIP, 107 patients (69%)
underwent operation with complete resection (R0) in 74% (79 of
107 patients). Downstaging (N2 to N0) after surgery was 29%.
Operative mortality rate was 2.8%. Twenty-one days (median) after
surgery, 79 patients were randomized to adjuvant NIP (47%) or
control (53%). Tolerance of adjuvant NIP: 12.5% G3 to 4 nausea/
vomiting, 19% G3 alopecia, 6% G3 infection, and G3 asthenia.
Overall median survival 32.3 versus 31.8 months in the observation
and NIP arms, respectively.
Conclusions: NIP allows 74% of R0 with no surgery delay. The few
number of randomized patients did not allow to conclude on the
efficacy of adjuvant chemotherapy.
Key Words: Triplet combination, Downstaging, Stage III, Non-
small cell lung cancer, Neo-adjuvant chemotherapy, Adjuvant che-
motherapy.
(J Thorac Oncol. 2008;3: 152–157)
Stage III non-small cell lung cancer (NSCLC) is a combi-nation of different conditions with different strategies of
treatment. Even if completely resected, patients with ipsilat-
eral mediastinal lymph nodes (N2) involvement will develop
distant metastasis.1
In fact, complete resection for patients with stage IIIa is
feasible in selected cases but the 5 years’ survival of patients
presenting clinical evidence of N2 disease remains poor,
about 8%, even in patients completely resected.2
The role of induction chemotherapy (CT) in the treatment
of stage III patients remains uncertain. Several phase II showed
encouraging results reducing the tumor bulk in 50 to 70% of
patients. Two small phase III trials performed at the same
time in Europe and North America3 demonstrated signifi-
cant benefit in terms of median survival versus surgery
alone. Unfortunately, Depierre et al.4 showed, in a large
phase III trial, a significant reduction in development of
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distant metastasis in patients who received CT but with no
impact on the overall survival.
The combination of vinorelbine/ifosfamide/cisplatin
(NIP) reported high activity in several phases II and III
studies in terms of response rate and 1 to 2 years’ survival in
patients with stages IIIB and IV disease.5–7 Based on these
data, a phase II trial using this combination of three drugs in
locally advanced NSCLC reported an interesting 61% re-
sponse rate with 21.4 months of median survival.8
When the present study was set up, a meta-analysis on
adjuvant chemotherapy reported that the administration of CT
after complete surgical resection may reduce local treatment
failures by eradicating circulating tumor cells and subclinical
metastasis still present at the time of surgery.9 The objective
of the current study was to test the activity of a new schedule
of intravenous vinorelbine (on days 1 and 5) in combination
with ifosfamide/mesna and cisplatin (on day 1) every 21 days
as primary chemotherapy in patients with previously un-
treated stage III A/B NSCLC, to determine both the tolerance
and the efficacy of this combination in terms of response rate
(clinical and pathologic), lymph node downstaging (N2 to
N0), and overall survival.
The protocol followed the recommendations of the
Helsinki Declaration and was approved by the Ethics Com-
mittee of the participating institutions.
PATIENTS AND METHODS
Main Inclusion and Exclusion Criteria
Patients to be included in this trial had to present
histologic and/or cytologic evidence of NSCLC, locally ad-
vanced disease (T3/T4 N0 or IIIa tumors), without any
previous treatment, aged more than 18, with Eastern Coop-
erative Oncology Group (ECOG) performance status 2 and
life expectancy 3 months, at least one assessable lesion,
with blood and biochemical parameters within the normal
ranges for each institution and had to have signed the in-
formed consent. Additional clinical features which precluded
entry to the trial were superior vena cava syndrome, central
nervous system metastasis, and second malignancy (except
adequately treated basal cell carcinoma of the skin and
carcinoma in situ of the uterine cervix). Active infectious
disease, pregnancy, neurologic disorders which could inter-
fere with the evaluation of neurologic toxicity and mentally
incapacitated patients, family, social or environmental con-
ditions impairing adequate follow-up and protocol compli-
ance were also excluded.
Patients participating in other investigational drug trials
during the previous 30 days, or pregnant or breast-feeding
were not eligible to participate in the study.
Pretreatment evaluation was completed within 2 weeks
before entry on study including clinical examination, chest
radiographs, chest computed tomography scan, abdominal/
pelvic ultrasound or computed tomography scan, bronchos-
copy, fine-needle aspiration or mediatinoscopy (only if the
patient presented with N), brain computed tomography
scan, and bone scan (only if clinical indicated). Efficacy and
tolerance were evaluated according to the World Health
Organization (WHO) criteria.
Treatment Plan
The NIP chemotherapy was administered as follows:
vinorelbine (N) 25 mg/m2 IV on days 1 and 5, ifosfamide/
mesna (I) 3 g/m2 on day 1, cisplatin (P) 80 mg/m2 IV on day
1 repeated every 21 days. Three courses of NIP were given
unless rapid disease progression occurred.
Chemotherapy doses were not escalated in this proto-
col. All three drugs could be reduced depending on the WHO
grade (3–4) of toxicity from 50 to 100%. Dose reduction was
allowed based on hematological, neurologic, hepatic, or renal
toxicity. Low blood counts at day 21 led to treatment delays
of 1 or 2 weeks until blood recovery (whole blood cell
3000/mm3, absolute neutrophil count 1500/mm3, plate-
lets 100,000/mm3). A maximum delay of 3 weeks was
allowed, beyond which the treatment was discontinued and
the patient withdrew from the study. For other grade 3 to 4
toxicity, the same rules were applied. Monitoring of the full
blood count before day 21 was not made systematically and
nadir counts were therefore not documented. Preventive col-
ony-stimulating factors were not allowed except in case of
febrile neutropenia and dose reduction was required for the
subsequent cycle.
Grade 3 to 4 neurologic toxicity (including paresthesia,
muscle weakness, or paralytic ileus) resulted in treatment
discontinuation.
Chemotherapy Administration
Vinorelbine (Navelbine) was administered in a 6- to
10-minute infusion followed by a free running 500 ml normal
saline solution for rinsing the vein; ifosfamide was diluted in
500 ml of normal saline solution with mesna 3 g/m2 on day
1 and infused more than 3 hours. Cisplatin was diluted in 250
ml of normal saline solution and administered more than 1
hour and within 1 hour after the end of infusion of vinorel-
bine. Cisplatin hydration and antiemetic therapy would be
given according to the center clinical practice. All three drugs
were administered every 21 days. Before receiving each
cycle, patients had to have a complete blood count and
biochemical evaluation. Moreover, a blood count had to be
repeated before vinorelbine administration on day 5.
Surgery
After the third course, a full assessment was performed.
Operable patients with complete response, partial response,
or stable disease underwent operation. If no response could
be observed, patients were withdrawn from the study.
Adjuvant Chemotherapy and Follow-Up
After operation, only patients with complete resection
(R0) were randomized; patients partially resected or not
resected were withdrawn from the study.
Thus, patients were randomly allocated to either two
further cycles of chemotherapy with the same schedule as
during neoadjuvant (arm A) or to observation without any
treatment (arm B). Radiotherapy was not allowed in either
group. Patient removed from study had to be evaluated for the
calculation of survival rates. All patients were routinely
followed by physical examination, complete blood count,
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chemistry, thoracic computed tomography scan, and upper
abdominal computed tomography scan.
Statistical Considerations
For the patients subjected to induction treatment, fol-
lowed by surgery alone the expected 2-year survival was
25%. For a suitable additional benefit from postoperative NIP
an absolute improvement in the 2-year survival with at least
45% of patients alive at 2 years was planned.
To have 90% confidence, with a two-sided 5% level
test, for detecting the above difference in survival, 62 patients
were needed to be randomized. Taking into account that 20 to
30% of included patients would fail the induction treatment
150 patients were needed to be included. The number of
patients lost to follow-up was evaluated at 10% of the total
number of subjects. Therefore, the total sample size for the
study was of 150 eligible patients with 62 patients included in
each treatment group.
Secondary endpoints included disease-free survival and
safety. Time-dependent parameters were described using
Kaplan-Meier curves and life tables by treatment arm. Over-
all survival and disease-free survival were compared using a
two-sided logrank test.
Overall survival was defined as the time elapsed
from the date of registration on one hand and randomiza-
tion on the other hand until death because of any cause or
to last follow-up. Patients alive at the cutoff date or lost to
follow-up were censored at the date of last news. Disease-
free survival was defined as the time elapsed from the date
of randomization until relapse or death because of any
cause or last follow-up date. Patients without relapse at the
cutoff date or lost to follow-up were censored at the date
of last news.
Maximum WHO grade (or severity) was reported by
cycle and by patient for hematological and nonhematological
toxicities.
Continuous data were summarized with the following
items: frequency, median, range, mean, and standard error if
relevant. Categorical data were summarized in contingency
tables with frequencies and percentages of each modality
(including missing data modality).
All analyses were performed using SAS system soft-
ware version 8.2 (SAS Institute, Inc., Cary, North Carolina)
for Windows.
RESULTS
From January 1999 through October 2002, a total of
156 patients were included (Figure 1). The study has been
closed prematurely because of the low rate of inclusions, with
only the half of the planned patients randomized after 4-year
inclusion period.
Of the 156 patients included in the protocol, 155
received the induction treatment. Only one patient died just
before to be treated because of progression. Although this
patient was excluded from the analysis, he was included in
the patient characteristics (Table 1).
Median age was 59 years (range 35–75 years) and the
most common histology was squamous cell (52% of the
population). All but two patients presented a performance
status 0 to 1. Clinical stage was determined according to the
baseline computed tomography scan. All patients presenting
N positive at the computed tomography scan received a
mediastinoscopy for histologic confirmation. Most of the
patients (65%) presented stage IIIa, 28% stage IIb, and 7%
stage IIIb. At the beginning of the study, only stage IIIa was
eligible for this protocol that included T3N0. After the
changes of the classification and the introduction of T3N0
into stage IIb,10 these patients continued to enter into the
study, explaining why almost one third of patients had
stage IIb.
Induction CT
Patients received a total of 435 cycles of CT. The
median number of cycles was 3 (range, 1–3) with 136
patients receiving the whole number of cycles as per protocol.
The relative dose intensity for vinorelbine, ifosfamide, and
cisplatin was 97, 98, and 98.5%, respectively.
FIGURE 1. Study flow chart.
TABLE 1. Patients Characteristics (n  156)
No. of Pts Percent
Median age, yr (range) 59 (35–75)
Male 133 85
Female 23 15
Histology
Squamous cell 82 52
Adenocarcinoma 48 31
Large cell carcinoma 9 6
NSCLC (NOS) 17 11
Stage at diagnosis
IIB 43 28
IIIA 102 65
IIIB 11 7
Performance status
0–1 154 99
2 2 1
Median T diameter, cm (range) 5.5 (1.2–10.6)
N0 53 34
N1 2 1
N2 101 65
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Response to induction CT
The results of the induction step are listed in the Table
2. Thirteen patients were considered as not assessable. The
reasons are death (six patients), refusal (two patients), lost of
follow-up (one patient), toxicity (one patient), acute pancre-
atitis (one patient), investigator decision (one patient), un-
known (one patient). The six deaths occurred for toxicity in
three patients (1.9%), sudden death in one (0.6%), heart
attack in one (0.6%), and complication of malignant disease
in one (0.6%).
The overall response rate was 52.6% in the intent-to-
treat (ITT) population and 57.3% in the assessable popula-
tion. Instead, 22.4% of ITT patients and 24.5% of assessable
patients had stable disease, 16.7 and 18.2% progressed to the
induction CT in the ITT and assessable patients, respectively.
Surgical Outcomes
Overall, 107 of 155 treated patients (69%) were eligible
for operation (Table 3). The delay between the last NVB
administration and operation was 32 days (range, 21–67 days).
Lobectomy was performed in 55 patients (52%); it was
right in 35 patients (65%), left in 19 (35%), and for 1 patient
the site was not specified. Pneumonectomy was performed in
42 patients (39%). It was right in 20 patients (49%) and left
in 21 patients (51%) and for 1 patient the site was not
specified. A right atypical segmentectomy was performed in
only one patient (1%). Finally, in nine patients only an
exploratory thoracotomy (8%) was performed.
A complete resection (R0) was possible in 79 of 107
patients (74%). In five patients, there was not tumor left
(pathologic complete response, pCR) (5%) and downstaging
from N2 to N0 was seen in 29% of the patients.
Only three patients presented perioperative complica-
tions: intestinal obstruction (one patient), bronchial infection
(one patient), and infection with empyema (one patient).
Three patients died within 30 days after surgery: one patient
for respiratory insufficiency, one for acute myocardium in-
farction, and one for pulmonary edema.
Adjuvant Treatment
All 79 patients with complete resection were random-
ized to either two more cycles of NIP chemotherapy (37
patients) or observation (42 patients).
Survival
After a median follow-up of 48 months from registra-
tion, the median survival was 31.8 months in the NIP arm and
32.3 months in the observation arm (Figure 2). Disease-free
survival was identical in both arms, 16.8 months (Figure 3).
Overall survival at 1, 2, and 3 years was of 91.9, 62.2,
and 48.7% in the treatment arm and of 85.7, 59.5, and 47.1%
in the observation arm (Table 4).
If we consider median survival from randomization,
there was neither difference in terms of median survival: 27.8
versus 28.7 months in the NIP and observation arms, respec-
tively (Figure 4).
Tolerance
One hundred and fifty-three patients received at least
one cycle of CT and were assessable for tolerance.
FIGURE 2. Overall survival from registration.
FIGURE 3. Disease-free survival from registration.
TABLE 2. Response to Induction Chemotherapy
ITT Assessable
No.
of Pts Percent
No.
of Pts Percent
Clinical CR 5 3.2 5 3.5
Partial response 77 49.4 77 53.8
ORR (95% CI) 82 52.6 (44.4–60.6) 82 57.3 (48.8–65.6)
No change 35 22.4 35 24.5
Progressive disease 26 16.7 26 18.2
Not evaluable 13 8.3 — —
Total 156 100 143 100
TABLE 3. Type of Surgery
Right Left
n Percent n Percent
Lobectomy (n  55)a (52%) 35 65 19 35
Pneumonectomy (n  42)a (39%) 20 49 21 51
Explorative thoracotomy (n  9) (8%) 3 33 6 67
Atypical segmentectomy (n  1) (1%) 1 100 — —
Total 59 46
a For one patient each, the side is not specified.
Journal of Thoracic Oncology • Volume 3, Number 2, February 2008 Cisplatin-Based Three Drugs Combination
Copyright © 2008 by the International Association for the Study of Lung Cancer 155
Febrile neutropenia was reported in 31 patients (20%),
and it was the cause of death of two patients. Grade 3 to 4
anemia was rare, only in six patients (4%) (Table 5).
Among grade 3 to 4 nonhematological toxicities during
neoadjuvant treatment, the most frequent was alopecia in
25.5% of patients, followed by nausea/vomiting (11%), as-
thenia (10%), anorexia (6.5%), pain no otherwise specified
(5%), and infection (6.5%). Other toxicities were rare and
accounted for less than 5%.
DISCUSSION
The theoretical benefits in performing induction CT
before surgery in locally advanced NSCLC mainly include
the cytoreduction of the bulky disease (downstaging) and the
early control of the micrometastasis.
During the last 10 years, several phase II studies have
shown that induction CT allowed to perform complete resec-
tion with pCR evidenced in 5 to 15%, being predictive of
long-term survival. A phase III study failed to show any
difference in terms of survival for the neoadjuvant treatment.
Moreover, patients with stages Ib and II had more advantages
from neoadjuvant than patients with stage IIIa. Nevertheless,
this data, although interesting, have to be interpreted with
caution as the study was not stratified by stage.4
In the current study, 155 patients received CT as
induction. The response rates of 57% in assessable patients
are in line with the results obtained by other phase III trials as
well the pCR of 5%.
Concerning the choice of a combination of three drugs
instead of a doublet, at the time the protocol was written,
there was no final conclusion about two or three drugs
combination, whereas in metastatic disease doublets seem to
do better than three drugs combinations.7 Thus, this question
remains still open for locally advanced disease. The number
of cycles needs some considerations. At the time of the study
implementation, there were no data available evaluating if
four cycles were better than two cycles of adjuvant chemo-
therapy. Thus we decided to keep only two cycles consider-
ing that the previous two cycles given as neoadjuvant che-
motherapy may impact on controlling the micrometastasis.
The NIP combination did not increase postoperative
complications even in patients with pneumonectomy.
In a meta-analysis carried out by Andre et al.,11 neo-
adjuvant chemotherapy did not increase perioperatory mor-
tality. In our study, only six patients showed complication or
death, which represented 6%, in line with the data presented
by Andre et al.
Large phase III trials reported that adjuvant CT is
useful in stages II and III NSCLC, but the current trial failed
to show any advantage of such approach, because of the low
number of randomized patients, as well probably to the use of
a triple combination chemotherapy which so far has not
reported improvement in survival.
In our experience, the NIP combination was well tol-
erated with acceptable hematological/ nonhematological tox-
icity. The febrile neutropenia rate of 20% was quite higher
but seldom complicated.
The three drugs combination (NIP) demonstrated to be
effective in patients with unresectable pN2/bulky T4 tumors
with optimal tumor shrinkage: 74% complete resection (R0)
and downstaging (N2 to N0) confirmed by surgery in 29% of
the patients.
Surgery was performed on time, within a median delay
of 32 days after the last administration of NIP. Complica-
tions/deaths were rare after operation.
New approaches should be investigated to allow higher
pCR with eventually combining chemotherapy with other
treatment as radiotherapy. Recent data confirms that improve-
FIGURE 4. Overall survival from randomization.
TABLE 4. Overall Survival from Registration
NIP (n  37) Observation (n  42)
Median survival (m) 31.8 32.3
Relapse-free survival (m) 16.8 16.8
1-yr survival (%) 91.9 85.7
2-yr survival (%) 62.2 59.5
3-yr survival (%) 48.7 47.1
Deaths 22 (59.5%) 24 (57.1%)
TABLE 5. Main Haematological Adverse Events (per
Assessable Patient for Toxicity) Grade 3–4 WHO
Classification
Neoadjuvant
(n  153)
Adjuvant
(n  29)
Control
(n  28)
n Percent n Percent n Percent
Anemia 6 4 — — — —
Neutropenia 5 3 — — — —
Thrombocytopenia — — — — — —
Death 6a 4 1 3 — —
(n  153) (n  32) (n  35)
Nausea/vomiting 17 11 4 12.5 — —
Diarrhea 5 3 — — — —
Alopecia 39 25.5 6 19 — —
Infection 10 6.5 2 6 1 3
Asthenia 15 10 2 6 1 3
Pain 8 5 — — 2 6
Anorexia 10 6.5 — — 1 3
a Only because of toxicity (2%).
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ment in survival may be achieved by this combination in
those patients with pCR. In absence of pCR no advantages
seem to be reported by the addition of surgery.12
Additional research should be focused on treatment
customization based on the biology of the tumor, according
for example, either to the expression of BRCA113 or to the
sensitivity to targeted agents.
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